Table 1. Prevalence and Nature of Clinically Significant Drug Interactions in Kenya.

Co-prescribed drug pairs	No. of interactions(% of 432 CSDIs*)
Major interactions
LPVr + artemether/lumefantrine	1 (0.2)
LPVr + fluoxetine	2 (0.5)
LPVr + rifampicin	3 (0.7)
Efavirenz + rifampicin	76 (17.6)
Nelfinavir + lansoprazole	40.9)
Nelfinavir + omeprazole	4 (0.9)
Nevirapine + ketoconazole	27 (6.3)
Nevirapine + rifampicin	45 (10.4)
Moderate interactions
LPVr + ketoconazole	2 (0.5)
Efavirenz + ketoconazole	10 (2.3)
Efavirenz + artemether/lumefantrine	5 (1.2)
Nevirapine + artemether/lumefantrine	24 (5.6)
Nevirapine + fluconazole	97 (22.5)
Nevirapine + prednisone	106 (24.5)
Zidovudine + dapsone	1 (0.2)
Zidovudine + fluconazole	20 (4.6)
Zidovudine + rifampicin	5 (1.2)

*occurring in 334 individuals.